search
Back to results

Acupuncture for Patients With Major Depressive Disorder

Primary Purpose

Major Depressive Disorder

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
acupuncture
Sponsored by
Chengdu University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring acupuncture, major depressive disorder, randomized controlled trial

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Right-handed participants aged between 18 to 60 years;
  2. participants diagnosed with mild to moderate major depressive disorder(MDD), and meet the diagnostic criteria of mild to moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition (DSM-5);
  3. participants with score of HAMD-24 between 8 to 35;
  4. participants without anti-depressive medication more than 3 months;
  5. participants willing to comply with the study protocol;
  6. participants willing to sign informed consent form.

Exclusion Criteria:

  1. participants with severe medical visceral condition and chronic diseases, such as hypertension, coronary heart disease, hyperthyroidism, hypothyroidism or diabetes and other endocrine system diseases;
  2. participants with brain organic diseases: such as birth injury, trauma, encephalitis, tumor, etc.;
  3. participants with Peripheral nerve and muscular system diseases;
  4. participants with severe anxiety, obsessive-compulsive disorder, or a history of mania or hypomania;
  5. Recently taken drugs that may cause mood disorders;
  6. Severe bleeding tendency, allergic constitution and skin disease patients;
  7. pregnant or lactation women;
  8. Persons with visual and hearing disabilities;
  9. Participants with pacemakers, deep brain stimulators, vagus nerve stimulators, metal internal fixators, etc
  10. participate in other clinical trials at the same time

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Sham Comparator

    No Intervention

    Arm Label

    acupuncture

    sham acupuncture

    waiting-list

    Arm Description

    5 sessions of acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the acupoints. Each session will last 30 minutes.

    5 sessions of sham acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on non-acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the non-acupoints. Each session will last 30 minutes.

    Outcomes

    Primary Outcome Measures

    score of Hamilton Depression Rating Scale-24
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on the Hamilton Depression Rating Scale (HAMD)-24

    Secondary Outcome Measures

    score of self-rating depression scale
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on self-rating depression scale (SDS)
    score of Hamilton Anxiety Rating Scale
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on Hamilton Anxiety Rating Scale (HAMA)
    score of Social Disability Screening Schedule
    change of score of Social Disability Screening Schedule (SDSS)
    score of Pittsburgh sleep quality index (PSQI)
    change of score of Pittsburgh sleep quality index (PSQI)
    motor threshold (MT)
    motor threshold (MT) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    Intra-cortical facilitation (ICF)
    Intra-cortical facilitation (ICF) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    cortical resting period (CSP)
    cortical resting period (CSP) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer [Time Frame: baseline, after intervention(4 week), after follow-up(4 week)]
    intra-cortical inhibition (ICI)
    intra-cortical inhibition (ICI) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    IAPS Evoked Event-related Potentials (ERP)
    IAPS Evoked Event-related Potentials (ERP)
    Evoked Event-related Potentials (ERP) in TMS-EEG
    Evoked Event-related Potentials (ERP) in TMS-EEG
    Adverse events
    Adverse events

    Full Information

    First Posted
    October 25, 2021
    Last Updated
    October 25, 2021
    Sponsor
    Chengdu University of Traditional Chinese Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05106868
    Brief Title
    Acupuncture for Patients With Major Depressive Disorder
    Official Title
    Acupuncture for Patients With Major Depressive Disorder: Study Protocol of a Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    November 1, 2021 (Anticipated)
    Primary Completion Date
    December 30, 2022 (Anticipated)
    Study Completion Date
    June 30, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Chengdu University of Traditional Chinese Medicine

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Several studies investigating acupuncture for major depressive disorder (MDD) have been carried out. However, investigators found the results were in high heterogeneity and poor methodological quality. Thus, investigators intend to provide high quality of the effectiveness and safety of acupuncture for MDD.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Major Depressive Disorder
    Keywords
    acupuncture, major depressive disorder, randomized controlled trial

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    123 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    acupuncture
    Arm Type
    Experimental
    Arm Description
    5 sessions of acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the acupoints. Each session will last 30 minutes.
    Arm Title
    sham acupuncture
    Arm Type
    Sham Comparator
    Arm Description
    5 sessions of sham acupuncture per week for 4 weeks. In each session, acupuncture will be applied bilaterally on non-acupoints. We will use transcutaneous electric acupoints stimulation (HANS; Han's acupoints nerve stimulator, HANS-200, Nanjing, China) to stimulate the non-acupoints. Each session will last 30 minutes.
    Arm Title
    waiting-list
    Arm Type
    No Intervention
    Intervention Type
    Device
    Intervention Name(s)
    acupuncture
    Intervention Description
    Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
    Primary Outcome Measure Information:
    Title
    score of Hamilton Depression Rating Scale-24
    Description
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on the Hamilton Depression Rating Scale (HAMD)-24
    Time Frame
    change from baseline to 4 weeks after intervention, after follow-up(4 week)
    Secondary Outcome Measure Information:
    Title
    score of self-rating depression scale
    Description
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on self-rating depression scale (SDS)
    Time Frame
    baseline, after intervention(4 week), after follow-up(4 week)
    Title
    score of Hamilton Anxiety Rating Scale
    Description
    Reduction in the severity of depression, measured at the end of the intervention primarily as a continuous variable on Hamilton Anxiety Rating Scale (HAMA)
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    score of Social Disability Screening Schedule
    Description
    change of score of Social Disability Screening Schedule (SDSS)
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    score of Pittsburgh sleep quality index (PSQI)
    Description
    change of score of Pittsburgh sleep quality index (PSQI)
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    motor threshold (MT)
    Description
    motor threshold (MT) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    Intra-cortical facilitation (ICF)
    Description
    Intra-cortical facilitation (ICF) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    cortical resting period (CSP)
    Description
    cortical resting period (CSP) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer [Time Frame: baseline, after intervention(4 week), after follow-up(4 week)]
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    intra-cortical inhibition (ICI)
    Description
    intra-cortical inhibition (ICI) measured by Brain Ultimate Combined with MEB-2312 EMG/evoked potentiometer
    Time Frame
    baseline, after intervention(4 week) , after follow-up(4 week)
    Title
    IAPS Evoked Event-related Potentials (ERP)
    Description
    IAPS Evoked Event-related Potentials (ERP)
    Time Frame
    baseline, after intervention(4 week), after follow-up(4 week)
    Title
    Evoked Event-related Potentials (ERP) in TMS-EEG
    Description
    Evoked Event-related Potentials (ERP) in TMS-EEG
    Time Frame
    baseline, after intervention(4 week), after follow-up(4 week)
    Title
    Adverse events
    Description
    Adverse events
    Time Frame
    during intervention(4 week)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Right-handed participants aged between 18 to 60 years; participants diagnosed with mild to moderate major depressive disorder(MDD), and meet the diagnostic criteria of mild to moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition (DSM-5); participants with score of HAMD-24 between 8 to 35; participants without anti-depressive medication more than 3 months; participants willing to comply with the study protocol; participants willing to sign informed consent form. Exclusion Criteria: participants with severe medical visceral condition and chronic diseases, such as hypertension, coronary heart disease, hyperthyroidism, hypothyroidism or diabetes and other endocrine system diseases; participants with brain organic diseases: such as birth injury, trauma, encephalitis, tumor, etc.; participants with Peripheral nerve and muscular system diseases; participants with severe anxiety, obsessive-compulsive disorder, or a history of mania or hypomania; Recently taken drugs that may cause mood disorders; Severe bleeding tendency, allergic constitution and skin disease patients; pregnant or lactation women; Persons with visual and hearing disabilities; Participants with pacemakers, deep brain stimulators, vagus nerve stimulators, metal internal fixators, etc participate in other clinical trials at the same time
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Zhong Zheng, PhD
    Phone
    18980601861
    Email
    zhengzhong1963@163.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Rongjiang Jin
    Email
    cdzyydxjrj@126.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jian Huang
    Organizational Affiliation
    Institute of Science and Technology Development, Sichuan University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Acupuncture for Patients With Major Depressive Disorder

    We'll reach out to this number within 24 hrs